Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Binge Eating Disorder - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape. Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 2 and 6 respectively. Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Binge Eating Disorder - Overview Binge Eating Disorder - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Binge Eating Disorder - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Binge Eating Disorder - Companies Involved in Therapeutics Development Chronos Therapeutics Ltd F. Hoffmann-La Roche Ltd Heptares Therapeutics Ltd Highland Therapeutics Inc India Globalization Capital Inc Novo Nordisk AS Omeros Corp Opiant Pharmaceuticals Inc Shire Plc Sunovion Pharmaceuticals Inc Binge Eating Disorder - Drug Profiles amphetamine MR - Drug Profile Product Description Mechanism Of Action R&D Progress CTDP-002 - Drug Profile Product Description Mechanism Of Action R&D Progress dasotraline hydrochloride - Drug Profile Product Description Mechanism Of Action R&D Progress IGC-504 - Drug Profile Product Description Mechanism Of Action R&D Progress lisdexamfetamine dimesylate - Drug Profile Product Description Mechanism Of Action R&D Progress OMS-527 - Drug Profile Product Description Mechanism Of Action R&D Progress OPNT-001 - Drug Profile Product Description Mechanism Of Action R&D Progress RO-5256390 - Drug Profile Product Description Mechanism Of Action R&D Progress Saxenda - Drug Profile Product Description Mechanism Of Action R&D Progress SERx-480 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress Binge Eating Disorder - Dormant Projects Binge Eating Disorder - Discontinued Products Binge Eating Disorder - Product Development Milestones Featured News & Press Releases Sep 14, 2017: Sunovion to Present Data on Dasotraline at the 2017 Psych Congress Aug 31, 2017: Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD May 23, 2017: Sunovion Announces Positive Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Adults with Binge Eating Disorder at Annual American Psychiatric Association Meeting May 16, 2017: Sunovion to Present Data on Dasotraline at Annual American Psychiatric Association Meeting Showcase Jan 13, 2017: Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder Oct 25, 2016: First And Only Medication Approved In Canada For The Treatment Of Binge Eating Disorder Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder Oct 06, 2016: Study Finds New Approach to Block Binge Eating Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline Jul 22, 2015: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder Jun 13, 2015: PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate May 11, 2015: Shire to Present New Research at American Psychiatric Association Annual Meeting Jan 30, 2015: Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder Sep 15, 2014: Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Binge Eating Disorder, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Binge Eating Disorder - Pipeline by Chronos Therapeutics Ltd, H2 2017 Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 Binge Eating Disorder - Pipeline by Heptares Therapeutics Ltd, H2 2017 Binge Eating Disorder - Pipeline by Highland Therapeutics Inc, H2 2017 Binge Eating Disorder - Pipeline by India Globalization Capital Inc, H2 2017 Binge Eating Disorder - Pipeline by Novo Nordisk AS, H2 2017 Binge Eating Disorder - Pipeline by Omeros Corp, H2 2017 Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals Inc, H2 2017 Binge Eating Disorder - Pipeline by Shire Plc, H2 2017 Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc, H2 2017 Binge Eating Disorder - Dormant Projects, H2 2017 Binge Eating Disorder - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
